PEG-somatropin
Phase 2Biologic
Changchun GeneScience Pharmaceutical Co., Ltd.PEG-somatropin is one of 5 biologic programs targeting Short stature. It is currently in Phase 2.
1
Indications
10
Total Trials
2
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Short Stature
#DrugCompanyPhaseTrials
1Voxzogo
BioMarin PharmaceuticalPhase 2
PEG-somatropin
Changchun GeneScience Pharmaceutical Co., Ltd.Phase 2
Recombinant Human Growth Hormone
Changchun GeneScience Pharmaceutical Co., Ltd.Preclinical
Gnrha
SSecond Affiliated Hospital of Wenzhou Medical University
Preclinical
PEG-Rhgh
Changchun GeneScience Pharmaceutical Co., Ltd.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Growth Hormone Deficiency8 trials
Show 5 more trials
Short stature2 trials
A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature
Active, not recruiting·Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 2·NCT03255694·360 enrolled
Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 2·NCT03255694·360 enrolledClinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature
Active, not recruiting·Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 2·NCT02375620·96 enrolled
Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 2·NCT02375620·96 enrolledSources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PEG-somatropin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details